Announcement of voluntary disclosure of clinical trial approval notice for drug clinical trial of HP560 tablets used for the treatment of myelofibrosis (myeloproliferative tumor)
Announcement of voluntary disclosure of the clinical phase I/II trial application for HP537 for the treatment of hematological malignancies approved by the United States FDA.
Investor Relations Activity Record Form of Haichuang Pharmaceutical (June 17-26, 2024)
Announcement on the resignation of senior management personnel and adjustment of core technical personnel
CITIC Securities Co., Ltd.'s inspection opinion on the departure of core technicians of Haichuang Pharmaceutical Co., Ltd.
Haichuang Pharmaceutical Investor Relations Activity Record Form (May 15 to May 21, 2024)
Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Group Performance Briefing and the First Quarter 2024 Results Briefing
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Haichuang Pharmaceutical Co., Ltd.
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision Site Inspection Report on Haichuang Pharmaceutical Co., Ltd.
Report on the work of the Board of Supervisors for the year 2023
Announcement on the company's 2024 related transaction forecast
Special report on the storage and actual use of funds raised in 2023
“Independent Director's 2023 Debriefing Report” - Peng Yongchen
2023 Board Work Report
“Independent Director's 2023 Debriefing Report” - Wei Yuquan
“Independent Director's 2023 Debriefing Report” - Xue Yunkui
2023 Accounting Firm Performance Assessment Report
“Independent Director's 2023 Debriefing Report” - Zheng Yaguang
Special explanation by independent directors on the external guarantee situation
Independent opinions of independent directors on matters relating to the fourth meeting of the second board of directors of the company
No Data